|Salary:||From £36,500 subject to skills and experience|
|Placed On:||22nd March 2023|
|Closes:||11th April 2023|
Location: The Francis Crick Institute, Midland Road, London
You will be working closely with the UCLH-Crick Legacy study to support experimental design, cell sorting and heavy metal labelling in mass cytometry using PBMCs from study participants. You will also work with the Proteomics and Metabolomics STPs to undertake multi-dimensional profiling of plasma samples from participants in both Legacy and STIMULATE-ICP studies, testing for differences between both metabolic and inflammatory pathways in participants with either resolved or persistent symptoms following COVID-19.
This post spans two flagship, complementary COVID-19 studies. The UCLH-Crick Legacy study is a multicentre consortium built from Clinicians and Group Leaders from across the Crick Institute and University College London Hospitals that tackles issues at the front-line of the on-going pandemic.
Your role is critical to support the expanding scope of our laboratory work in COVID-19 immunology across Legacy, the WWW consortium and STIMULATE-ICP. Over the last 2 years these matched cohorts have generated detailed longitudinal metadata and associated samples encompassing the entire spectrum of COVID-19 infections in previously healthy adults. You will use biological samples from these rich resources to approach fundamental questions on the underlying biology of different clinical and immunological responses to COVID-19. You will work primarily within the UCLH-Crick Legacy study team, led by Dr Emma Wall, with Dr David Bauer, Dr Edward Carr and Dr Mary Wu and work closely with the Crick’s Flow Cytometry, Proteomic and Metabolomic STPs.
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.
The Crick was formed in 2015, and in 2016 it moved into a new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under in one building in Europe.
The Francis Crick Institute will be world-class with a strong national role. Its distinctive vision for excellence includes commitments to collaboration; developing emerging talent and exporting it the rest of the UK; public engagement; and helping turn discoveries into treatments as quickly as possible to improve lives and strengthen the economy.
Type / Role: